Boldine Improves Kidney Damage in the Goldblatt 2K1C Model Avoiding the Increase in TGF-β

Area of Science:

• Pharmacology
• Nephrology
• Natural Products

Background:

• Renovascular hypertension (RVH) involves oxidative stress and renin-angiotensin system (RAS) activation, leading to kidney damage.
• Transforming growth factor-beta (TGF-β) is linked to RAS activation and hypertensive renal damage progression.
• Boldine, a potent antioxidant alkaloid from the boldo tree, is investigated for its potential renoprotective effects.

Purpose of the Study:

• To evaluate the effect of boldine on kidney damage progression in a 2K1C rat model of RVH.
• To identify if boldine modulates RAS mediators, specifically angiotensin-converting enzyme 1 (ACE-1) and TGF-β.
• To assess boldine's impact on oxidative stress and inflammation markers in hypertensive kidneys.

Main Methods:

• Rats underwent 2K1C surgery to induce hypertension (≥180 mmHg) and were treated with boldine (50 mg/kg/day) or vehicle for six weeks.
• Kidney function assessed via proteinuria/creatininuria ratio (UProt/UCrea).
• Oxidative stress (TBARS), blood pressure (SBP), kidney damage (α-SMA, Col III), inflammation (ED-1, OPN), and RAS mediators (ACE-1, TGF-β) were measured.

Main Results:

• Boldine treatment significantly reduced proteinuria, plasma TBARS, and markers of kidney damage (α-SMA, Col III) and inflammation (ED-1, OPN) in 2K1C rats.
• Boldine administration prevented the elevation of ACE-1 and TGF-β levels observed in hypertensive rats.
• A slight reduction in systolic blood pressure (SBP) was noted in boldine-treated 2K1C rats, with no effect in controls.

Conclusions:

• Boldine demonstrates renoprotective properties in the 2K1C rat model of renovascular hypertension.
• The findings suggest boldine mitigates kidney damage by reducing oxidative stress, inflammation, and inhibiting key RAS components.
• Boldine holds potential as a therapeutic nutraceutical for managing hypertensive kidney disease.